Molecular targeted intervention for pancreatic cancer

Altaf Mohammed*, Naveena B. Janakiram, Shubham Pant, Chinthalapally V. Rao

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

28 Scopus citations


Pancreatic cancer (PC) remains one of the worst cancers, with almost uniform lethality. PC risk is associated with westernized diet, tobacco, alcohol, obesity, chronic pancreatitis, and family history of pancreatic cancer. New targeted agents and the use of various therapeutic combinations have yet to provide adequate treatments for patients with advanced cancer. To design better preventive and/or treatment strategies against PC, knowledge of PC pathogenesis at the molecular level is vital. With the advent of genetically modified animals, significant advances have been made in understanding the molecular biology and pathogenesis of PC. Currently, several clinical trials and preclinical evaluations are underway to investigate novel agents that target signaling defects in PC. An important consideration in evaluating novel drugs is determining whether an agent can reach the target in concentrations effective to treat the disease. Recently, we have reported evidence for chemoprevention of PC. Here, we provide a comprehensive review of current updates on molecularly targeted interventions, as well as dietary, phytochemical, immunoregulatory, and microenvironment-based approaches for the development of novel therapeutic and preventive regimens. Special attention is given to prevention and treatment in preclinical genetically engineered mouse studies and human clinical studies.

Original languageEnglish
Pages (from-to)1499-1542
Number of pages44
Issue number3
StatePublished - 10 Aug 2015
Externally publishedYes


  • Chemoprevention
  • Chemotherapy
  • Combination treatment
  • Drug development
  • Pancreatic cancer


Dive into the research topics of 'Molecular targeted intervention for pancreatic cancer'. Together they form a unique fingerprint.

Cite this